Cumberland Pharmaceuticals Inc (CPIX) — Titan Protect Analysis

CPIX

Cumberland Pharmaceuticals Inc

Healthcare · ·

$5.80

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$83M

Total market value of the company

Trailing P/E

N/A

Forward P/E

39.79

Based on estimated future earnings — lower means cheaper

Rev Growth

-22.0%

Year-over-year revenue change

Profit Margin

-17.6%

How much profit the company keeps from each dollar of revenue

ROE

-29.8%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

NONE

Consensus view from ? analysts covering this stock

About Cumberland Pharmaceuticals Inc

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy tr

https://www.cumberlandpharma.com

Country: United States Employees: 93 Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

1.081

Excellent risk-adjusted returns

Kelly Fraction

0.0563

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.421

Returns exceed worst-case losses — strong risk profile

Annual Return

102.2%

Historical annualised return based on price data

Max Drawdown

-71.9%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

-0.06

Very low correlation to market moves

52W High

$6.61

12% below the year high

52W Low

$1.85

214% above the year low

Avg Volume

982,250

Average daily shares traded — higher means easier to buy and sell

Short Ratio

0.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.49

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

47.27

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

82.9%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-34.3%

Profit from core operations before interest and tax

Free Cash Flow

$5M

Positive — the business generates more cash than it spends

Revenue (TTM)

$42M

Total revenue over the last 12 months

Net Income

$-7,382,835

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go